Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP grew its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 791.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 57,985 shares of the company's stock after purchasing an additional 51,482 shares during the quarter. GSA Capital Partners LLP owned approximately 0.12% of Mirum Pharmaceuticals worth $2,261,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of MIRM. Price T Rowe Associates Inc. MD boosted its stake in shares of Mirum Pharmaceuticals by 37.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,597,506 shares of the company's stock worth $40,131,000 after acquiring an additional 432,824 shares during the last quarter. Silvercrest Asset Management Group LLC raised its position in Mirum Pharmaceuticals by 64.6% in the first quarter. Silvercrest Asset Management Group LLC now owns 162,817 shares of the company's stock valued at $4,090,000 after purchasing an additional 63,871 shares during the period. Rice Hall James & Associates LLC raised its holdings in Mirum Pharmaceuticals by 6.9% in the 2nd quarter. Rice Hall James & Associates LLC now owns 229,730 shares of the company's stock valued at $7,854,000 after buying an additional 14,843 shares during the period. Candriam S.C.A. acquired a new position in Mirum Pharmaceuticals in the second quarter valued at about $17,384,000. Finally, Hennion & Walsh Asset Management Inc. raised its stake in shares of Mirum Pharmaceuticals by 64.9% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 104,770 shares of the company's stock valued at $3,582,000 after acquiring an additional 41,236 shares during the period.

Analysts Set New Price Targets

Several equities analysts have weighed in on MIRM shares. Cantor Fitzgerald lifted their target price on Mirum Pharmaceuticals from $50.00 to $60.00 and gave the company an "overweight" rating in a research report on Thursday, August 8th. HC Wainwright restated a "buy" rating and issued a $66.00 price objective on shares of Mirum Pharmaceuticals in a report on Friday, October 11th. Robert W. Baird raised their price objective on shares of Mirum Pharmaceuticals from $39.00 to $44.00 and gave the stock an "outperform" rating in a report on Thursday, August 8th. Evercore ISI increased their price objective on Mirum Pharmaceuticals from $62.00 to $66.00 and gave the company an "outperform" rating in a report on Thursday, August 8th. Finally, Leerink Partners increased their price target on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an "outperform" rating in a report on Thursday, October 17th. Ten equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Mirum Pharmaceuticals has an average rating of "Buy" and a consensus target price of $56.82.

Mirum Pharmaceuticals Trading Up 3.7 %

Shares of NASDAQ:MIRM traded up $1.54 during midday trading on Tuesday, reaching $43.15. The company's stock had a trading volume of 278,411 shares, compared to its average volume of 555,770. The firm has a market cap of $2.06 billion, a price-to-earnings ratio of -18.17 and a beta of 1.16. The business has a 50 day moving average price of $39.90 and a 200 day moving average price of $35.61. Mirum Pharmaceuticals, Inc. has a 1 year low of $23.14 and a 1 year high of $45.81. The company has a quick ratio of 3.09, a current ratio of 3.28 and a debt-to-equity ratio of 1.34.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.